Clinical trials: Breast Tumor Tissue
Breast Cancer, HER2-positive Breast Cancer
Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer
This phase II, multicenter, open-label, randomized controlled trial (FACET study) evaluates the efficacy and safety of fulvestaciclib, a novel oral CDK4/6 inhibitor, combined with anti-HER2 dual blockade (trastuzumab and…
- Conditions
- Breast Cancer, HER2-positive Breast Cancer, Hormone Receptor-positive Breast Cancer, HR+/HER2+ Breast Cancer
- Trial name
- FACET (NCT07716046)
- Testing
- Fulvestaciclib, Trastuzumab, Pertuzumab
- Volunteers
- 240 people
- Sponsor
- Fudan University
Metastatic Breast Cancer, Tumor
Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint Tumor
At a median follow-up of 33 months, the combination of anastrozole and NOLVADEX (tamoxifen citrate) did not demonstrate any efficacy benefit when compared to NOLVADEX (tamoxifen citrate) therapy given alone in all patients as…
- Conditions
- Metastatic Breast Cancer, Tumor, Muscle Neoplasms, Chronic Pain
- Trial name
- NASBP-B-09 (NCT06154590)
- Testing
- Method(s)1 Attribution, Method(s)2 Attribution,
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- DR. DIANE CHISESI NFS. MD. PHD.
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
This phase II trial studies the effect of avapritinib in treating malignant solid tumors that have a genetic change (mutation) in CKIT or PDGFRA and have spread to nearby tissue or lymph nodes (locally advanced) or other places…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
- Trial name
- NCT04771520
- Testing
- Avapritinib
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Neoplasm
Adjusting the Dose of Therapeutic Exercise to Prevent Neurotoxicity Due to Anticancer Treatment (ATENTO)
The purpose of this study is to determine whether a multimodal program based on therapeutic exercise and vagal activation techniques for newly diagnosed breast cancer women has better results in terms of neurotoxicity prevenion…
- Trial name
- ATENTO (NCT04583124)
- Testing
- ATENTO-B, ATENTO-T
- Where
- Spain
- Volunteers
- 42 people
- Sponsor
- Universidad de Granada
Breast Neoplasms
Cohort Study on Sequential ADC Therapy in HR-positive/HER2-negative Advanced Breast Cancer
The combination of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and endocrine therapy is the standard first-line treatment for advanced HR+ (hormone receptor-positive)/HER2- (human epidermal growth factor receptor 2-negative)…
- Trial name
- NCT07162259
- Testing
- First-line T-DXd followed by SG upon disease progression, First-line SG followed by T-DXd upon progression
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Yan Xue
Neoplasms, Breast Neoplasms
Rehabilitation of Cancer Survivors in Denmark: The Effect of a Psychosocial Rehabilitation Course
This randomized study evaluates the effect of a multi-focused, psychosocial 6-day residential rehabilitation course at a Danish rehabilitation centre for cancer survivors.
- Conditions
- Neoplasms, Breast Neoplasms, Colorectal Neoplasms, Prostatic Neoplasms
- Trial name
- NCT01086683
- Testing
- Psychosocial rehabilitation course
- Where
- Denmark
- Volunteers
- 513 people
- Sponsor
- Danish Cancer Society
Breast Cancer
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
This was a randomized, double-blind, placebo-controlled phase 2 clinical trial comparing the overall survival of women with advanced or metastatic HER2-negative breast cancer who received treatment with capecitabine in…
- Trial name
- NCT02120417
- Testing
- Ruxolitinib, Capecitabine
- Where
- 106 sites in United States, France and 4 more
- Volunteers
- 149 people
- Sponsor
- Incyte Corporation
Cancer, Breast Cancer
Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors
The purpose of this study is to determine the effectiveness of a digital health program called AYA STEPS, which is designed to help adolescent and young adult (AYA) cancer survivors manage symptoms and engage in recommended…
- Conditions
- Cancer, Breast Cancer, Colorectal Cancer, Sarcoma
- Trial name
- AYA STEPS (NCT06371768)
- Testing
- AYA Educational Information, AYA STEPS
- Where
- United States
- Volunteers
- 260 people
- Sponsor
- Duke University
Breast Cancer, Bone Metastases
Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis
The goal of this clinical research study is to find the highest tolerable dose of dasatinib and Zometa (zoledronic acid) that can be given in combination for the treatment of breast cancer that has spread to the bone.
- Trial name
- NCT00566618
- Testing
- Dasatinib, Zoledronic Acid
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Factors Influencing Decision-Making About the Use of Chemoprevention in Women at Increased Risk for Breast Cancer
RATIONALE: Learning about how patients make decisions about using chemoprevention may help doctors plan treatment in which more patients are willing to choose chemoprevention to reduce their breast cancer risk.
- Trial name
- NCT01399359
- Testing
- Counseling session, Questionnaire 1, Questionnaire 2
- Where
- United States
- Volunteers
- 1,023 people
- Sponsor
- NSABP Foundation Inc
Early Breast Cancer, Adjuvant Therapy
Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients
This study aims to evaluate the efficacy and safety of adjuvant endocrine therapy combined with dalpiciclib at different doses and durations in patients with hormone receptor (HR)-positive, HER2-negative early-stage breast…
- Conditions
- Early Breast Cancer, Adjuvant Therapy, Hormone Receptor Positive / HER2-negative Breast Cancer
- Trial name
- NCT07101159
- Testing
- Dalpiciclib, Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)
- Volunteers
- 200 people
- Sponsor
- Fujian Cancer Hospital
Breast Cancer
FBnTP Imaging of Breast Cancer
Our preclinical studies suggest the capacity of the positron emission tomography imaging agent 18F-fluorobenzyl triphenyl phosphonium (FBnTP) to detects early-stage small breast tumors (e.g., DCIS), and differentiates benign from…
- Trial name
- NCT02204462
- Testing
- FBnTP
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer
Positive Node Traced Before Neoadjuvant Chemotherapy (NAC)
To investigate this regression model by injecting and tracing carbon nanoparticles (CNs) into the fusion node prior to NAC in patients with breast cancer.
- Trial name
- NCT03355261
- Testing
- complete remission (CR) group, partial remission (PR) group, stable disease (SD) group
- Where
- 3 sites in China
- Volunteers
- 110 people
- Sponsor
- Shengjing Hospital
Breast Cancer
Bergonie Institute Breast Cancer Database
A database of breast cancer patients was established at Institute Bergonié since the 90s , to assess patients' survival, assess practice, search for prognostic factors.
- Trial name
- NCT02893761
- Where
- France
- Volunteers
- 30,000 people
- Sponsor
- Institut Bergonié
Breast Cancer
Investigation of Gene Mutations in Patients With Triple-negative and Patients With HER2+ Breast Cancer Adenocarcinoma
The present study is a transnational study in patients with high risk recurrent breast cancer who receive adjuvant chemotherapy with epirubicin and cyclophosphamide followed by docetaxel or paclitaxel.
- Trial name
- NCT04365790
- Where
- Greece
- Volunteers
- 500 people
- Sponsor
- Hellenic Cooperative Oncology Group
Breast Cancer
Breast Cancer Risk Biomarkers in Postmenopausal Women
This study is designed to gather information on how the prescription drug Lovaza™ which contains omega-3 fatty acids, affects blood and tissue risk biomarkers for breast cancer.
- Trial name
- NCT01252290
- Testing
- Lovaza™
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Carol Fabian, MD
Ovarian Cancer, Breast Cancer
A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer
Background: All cells go through cycles which allow them to divide. In normal cells, checkpoint kinase 1 (Chk1) and checkpoint kinase 2 (Chk2) (CHEK 2 (Chk1/2) stop cell division at various points to allow any damage to…
- Conditions
- Ovarian Cancer, Breast Cancer, Prostate Cancer
- Trial name
- NCT02203513
- Testing
- LY2606368
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- National Cancer Institute (NCI)
Triple-Negative Breast Cancer (TNBC)
A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
The aim of this study is to evaluate the efficacy and safety of ESG401 as first-line treatment in patients with unresectable recurrent or metastatic triple-negative breast cancer.
- Trial name
- NCT06732323
- Testing
- ESG401, Investigator's Choice Chemotherapy
- Where
- China
- Volunteers
- 504 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Breast Cancers
Three Dimensional (3D) Ultrasound in Predicting Response to Breast Cancer Therapies
The purpose of this study is to determine how well changes can be determined in malignant masses from ultrasound scans.
- Trial name
- NCT00721903
- Testing
- Ultrasound Scan, Mammography and Ultrasound
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Breast Cancer
A Study to Evaluate the Accuracy of a Breast Cancer Locator (BCL) in Patients With Palpable Cancers
In this study, the investigators will enroll women with palpable cancers to assess the accuracy of the Breast Cancer Locator (BCL) and the concomitant procedure as a vehicle to optimize and validate the approach in such surgical…
- Trial name
- NCT02550210
- Testing
- Breast Cancer Locator (BCL)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.